Form D · Biotechnology
IRX Therapeutics, Inc.
New York, NY · CIK 0001411920
Offering snapshot reported Aug 29, 2017 · SEC filing
- Reported sold
- $33.2M Offering amount: $33.2M
- Investors reported
- 98 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 30, 2016 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$13,237,234 → $33,230,669
- Reported investors68 → 98
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 29, 2017 | Amendment | $33,230,669 | $19,993,435vs Jan 12, 2017 | 98 | SEC filing |
| Jan 12, 2017 | Initial | $13,237,234 | No comparison | 68 | SEC filing |
| Nov 9, 2016 | Initial | $6,400,000 | No comparison | 4 | SEC filing |
| May 13, 2016 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Aug 17, 2015 | Amendment | $40,585,742 | $9,017,999vs Jan 15, 2015 | 230 | SEC filing |
| Jan 15, 2015 | Initial | $31,567,743 | No comparison | 222 | SEC filing |
| Mar 14, 2014 | Initial | $15,094,601 | No comparison | 104 | SEC filing |
| May 30, 2012 | Initial | $1,500,000 | No comparison | 105 | SEC filing |
| Jun 11, 2010 | Initial | $8,047,991 | No comparison | 163 | SEC filing |
| Jan 11, 2010 | Initial | $2,211,772 | No comparison | 33 | SEC filing |
| Sep 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-278212
Source: Form D, filed Aug 29, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles R. Cherington | Director |
| David H. Deming | Director |
| George P. Denny Iii | Director |
| John W. Hadden | Director |
| John W. Hadden Ii | Director, Executive |
| John D. Halpern | Director |
| Jeffrey Hwang | Executive |
| Jeffrey Hwuang | Executive |
| Mark W. Leuchtenberger | Director, Executive |
| Frank J. Loverro | Director |
| Ferid Murad | Director |
| Curtis P. Robb | Executive |
| Zygmund Roth | Executive |
| Monil Shah | Executive |
| John T. Spitznagel | Director |
| Howard H. Stevenson | Director |
| Edmund Truell | Director |
| Lawrence M. Wolf | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
654 Madison Avenue Suite 1601
New York, NY, 10065
New York, NY, 10065